(5alpha,11beta)-11-[4-(二甲基氨基)苯基]-5-羟基雌甾-9-烯-3,17-二酮环 3-(1,2-乙二基缩醛) | 91934-77-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: (5alpha,11beta)-11-[4-(二甲基氨基)苯基]-5-羟基雌甾-9-烯-3,17-二酮环 3-(1,2-乙二基缩醛)
• 中文别名: (5alpha,11beta)-11-[4-(二甲基氨基)苯基]-5-羟基雌甾-9-烯-3,17-二酮环3-(1,2-乙二基缩醛)
• 英文名称: 3,3-ethylenedioxy-5α-hydroxy-11β-[4-(N,N-dimethylamino)phenyl]-estr-9-en-17-one
• 英文别名: 11β-[4-(N,N-dimethylamino)phenyl]-3,3-[1,2-ethanediylbis(oxy)]-5α-hydroxyestr-9-en-17-one；3,3-ethylendioxy-5α-hydroxy-11β-[4-(dimethylamino)phenyl]estra-9-en-17-one；(5R,8S,11R,13S,14S)-11-(4-(dimethylamino)phenyl)-5-hydroxy-13-methyl-1,4,5,6,7,8,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17(2H)-one；3,3-ethylendioxy-5α-hydroxy-11β-[4-p-(dimethylamino)phenyl]estra-9-en-17-one；(5R,11R,13S,14S)-11-(4-(dimethylamino)phenyl)-5-hydroxy-13-methyl-1,4,5,6,7,8,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17(2H)-one；(5'R,11'R,13'S)-11'-[4-(dimethylamino)phenyl]-5'-hydroxy-13'-methyl-spiro[1,3-dioxolane-2,3'-2,4,6,7,8,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]-17'-one；3,3-Ethylenedioxy-11β-(4-dimethylaminophenyl)-5α-hydroxy-9-estren-17-one；3,3-ethylenedioxy-5a-hydroxy-11b-[4-(N,N-dimethylamino)phenyl]-estr-9-en-17-one；(5A,11B)-11-[4-(Dimethylamino)phenyl]-5-hydroxy-estr-9-ene-3,17-dione cyclic 3-(1,2-ethanediyl acetal)；(5'R,8'S,11'R,13'S,14'S)-11'-[4-(dimethylamino)phenyl]-5'-hydroxy-13'-methylspiro[1,3-dioxolane-2,3'-2,4,6,7,8,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]-17'-one
• CAS: 91934-77-9
• 化学式: C₂₈H₃₇NO₄
• 分子量: 451.606
• InChiKey: RUQVJLDZKPZLIG-KDPBODAISA-N

物化性质

• 沸点：
  633.8±55.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  33
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (5alpha,11beta)-11-[4-(二甲基氨基)苯基]-5-羟基雌甾-9-烯-3,17-二酮环 3-(1,2-乙二基缩醛) 生成 ethyl 3-[(8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methylspiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,2'-1,3-dioxolane]-17-yl]prop-2-ynoate
  参考文献：
  名称：

  TORELLI, V.;TEUTSCH, J. G.;PHILIBERT, D.

  摘要：

  DOI：
• 作为产物：
  描述：

  (5R,8S,11R,13S,14S)-11-(4-(dimethylamino)phenyl)-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydrospiro[cyclopenta[a]phenanthrene-3,2’-[1,3]dioxolane]-5,17(4H)-diol 在 aluminum isopropoxide 作用下， 以 环己酮 、 甲苯 为溶剂， 反应 3.0h， 以66%的产率得到(5alpha,11beta)-11-[4-(二甲基氨基)苯基]-5-羟基雌甾-9-烯-3,17-二酮环 3-(1,2-乙二基缩醛)
  参考文献：
  名称：

  [EN] INHIBITORS OF GLUCOCORTICOID RECEPTOR
  [FR] INHIBITEURS DE RÉCEPTEURS GLUCOCORTICOÏDES

  摘要：

  本发明一般涉及治疗癌症和高皮质醇血症的组合物和方法。本文提供了替代类固醇衍生物化合物和包含该类化合物的药物组合物。所述化合物和组合物对于抑制糖皮质激素受体是有用的。此外，所述化合物和组合物对于治疗癌症和高皮质醇血症是有用的。

  公开号：

  WO2017112902A1

文献信息

• 11-PHOSPHOROUS STEROID DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS
  申请人：Fiordeliso J. James

  公开号：US20070232570A1

  公开（公告）日：2007-10-04

  The present invention is directed to novel 11-phosphorous steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by a progesterone or glucocorticoid receptor.

  本发明涉及新颖的11-磷酸类固醇衍生物，含有它们的药物组合物以及它们在治疗受孕激素或糖皮质激素受体调节的疾病和症状中的应用。
• 17-PHOSPHOROUS STEROID DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS
  申请人：Jiang Weiqin

  公开号：US20070207982A1

  公开（公告）日：2007-09-06

  The present invention is directed to novel 17-phosphorous steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by a progesterone or glucocorticoid receptor.

  本发明涉及新颖的17-磷类固醇衍生物，含有它们的药物组合物以及它们在治疗受孕激素或糖皮质激素受体调节的疾病和症状中的用途。
• [EN] 11 beta -SUBSTITUTED PROGESTERONE ANALOGS
  申请人：RESEARCH TRIANGLE INSTITUTE

  公开号：WO1989012448A1

  公开（公告）日：1989-12-28

  (EN) An 11$g(b)-aryl-19-norprogesterone steroid of formula (I): wherein (i) R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OH, OC(O)CH3, or OC(O)R5, wherein R5 is C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or aryl, R2 is H, R3 is H, C1-4 alkyl, C2-4 alkenyl or C2-4 alkynyl, R4 is H, CH3, F or Cl, R6 is H, (CH3)2N, CH3O, CH3CO, CH3S, CH3SO, CH3SO2, and X is O or NOCH3; or (ii) R1 and R2 taken together are a carbon-carbon bond and R3, R4, R6 and X are as defined above; or (iii) R1 and R3 taken together are -CH2- or -N=N-CH2-, R2 is H and R4, R6 and X are as defined above; or (iv) R2 and R3 taken together are =CH2 and R1, R4, R6 and X are as defined above.(FR) L'invention concerne un 11$g(b)-aryle-19-norprogestérone stéroïde de la formule (I) dans laquelle (i) R1 représente H, alkyle C1-4, alkenyle C2-4, alkynyle C2-4, OH, OC(O)CH3, ou OC(O)R5, où R5 représente alkyle C2-8, alkenyle C2-8, alkynyle C2-8 ou aryle, R2 représente H, R3 représente H, alkyle C1-4, alkenyle C2-4 ou alkynyle C2-4, R4 représente H, CH3, F ou Cl, R6 représente H, (CH3)2N, CH3O, CH3CO, CH3S, CH3SO, CH3SO2, et X représente O ou NOCH3; ou (ii) R1 et R2 pris ensemble représentent une liaison carbone-carbone et R3, R4, R6 et X sont définis comme ci-dessus; ou (iii) R1 et R3 pris ensemble représentent -CH2- ou -N=N-CH2-, R2 représente H et R4, R6 et X sont définis comme ci-dessus; ou (iv) R2 et R3 pris ensemble représentent =CH2 et R1, R4, R6 et X sont définis comme ci-dessus.

  一种式子为(I)的11$g(b)-芳基-19-去甲孕酮类固醇，其中(i) R1为H、C1-4烷基、C2-4烯基、C2-4炔基、OH、OC(O)CH3或OC(O)R5，其中R5为C2-8烷基、C2-8烯基、C2-8炔基或芳基，R2为H，R3为H、C1-4烷基、C2-4烯基或C2-4炔基，R4为H、 、F或Cl，R6为H、( )2N、 O、 CO、 S、 SO或 SO2，X为O或NO ；或(ii) R1和R2一起为碳-碳键，R3、R4、R6和X如上所定义；或(iii) R1和R3一起为-CH2-或-N=N- -，R2为H，R4、R6和X如上所定义；或(iv) R2和R3一起为= ，R1、R4、R6和X如上所定义。
• Inhibitors of glucocorticoid receptor
  申请人：ORIC Pharmaceuticals, Inc.

  公开号：US11124537B2

  公开（公告）日：2021-09-21

  The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.

  本发明一般涉及治疗癌症和皮质醇过多症的组合物和方法。本发明提供了取代的类固醇衍生物化合物和包含所述化合物的药物组合物。所述化合物和组合物可用于抑制糖皮质激素受体。此外，所述化合物和组合物还可用于治疗癌症和皮质醇过多症。
• Novel phosphorus-containing 17β-side chain mifepristone analogues as progesterone receptor antagonists
  作者：Weiqin Jiang、George Allan、Xin Chen、James J. Fiordeliso、Olivia Linton、Pamela Tannenbaum、Jun Xu、Peifang Zhu、Joseph Gunnet、Keith Demarest、Scott Lundeen、Zhihua Sui

  DOI：10.1016/j.steroids.2006.07.003

  日期：2006.11

  A novel series of steroidal compounds were designed and synthesized with various phosphorus-containing groups on the 17 beta-side chain as progesterone receptor antagonists. The structure -activity relationships of these compounds are discussed. Selected compounds were tested in an rat progesterone-sensitive assay. Some of these compounds are more potent than mifepristone, with a better selectivity profile in differentiating progesterone receptor from glucocorticoid receptor.(C) 2006 Elsevier Inc. All rights reserved.